Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with ...
A second prostate-specific membrane antigen (PSMA) PET scan changed treatment plans for nearly half of patients whose first scan was negative, according to new research published in the July issue of ...
Five-year results from the NRG-GU003 Phase III trial show that a 25-fraction, five-week postoperative radiation schedule ...
KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study. Baseline PSMA PET/CT as a predictive ...
Experimental oral drug JNJ-6143 produced strong PSA and tumor responses in patients with heavily treated advanced prostate ...
Timing and uptake of germline testing in patients with somatic BRCA1/2 pathogenic or likely pathogenic variants in solid tumors: A real-world study from community oncology practices. Identifying ...
What matters in prostate cancer treatment is not simply removing the cancer. How much urinary and sexual function can be ...
CIRT leads to temporary urinary function decline, normalizing within three months and stable for five years. Prostate volume decreases significantly without ADT, remaining reduced for five years. T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results